APO Research
Talk to an analyst

APO RESEARCH · REPORT

TIGIT Therapies

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global TIGIT Therapies Market Outlook and Growth Opportunities 2026

30 December 2025194 pages

Choose your research edition.

Industry ResearchTIGIT Therapies Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal TIGIT Therapies Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal TIGIT Therapies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal TIGIT Therapies Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal TIGIT Therapies Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global TIGIT Therapies market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for TIGIT Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for TIGIT Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for TIGIT Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the TIGIT Therapies market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the TIGIT Therapies market include Arcus, Astellas, BMS, Compugen, Mereo BioPharma, Seattle Genetics, AstraZeneca, BeiGene and Hengrui Medicine, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global TIGIT Therapies market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of TIGIT Therapies and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents TIGIT Therapies revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global TIGIT Therapies market.

TIGIT Therapies Segment by Company

Arcus

Astellas

BMS

Compugen

Mereo BioPharma

Seattle Genetics

AstraZeneca

BeiGene

Hengrui Medicine

Junshi Biosciences

Roche

Merck

Innovent Biologics

TIGIT Therapies Segment by Type

Monotherapy

Combination Therapy

TIGIT Therapies Segment by Application

Cell Carcinoma

Solid Tumor

TIGIT Therapies Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global TIGIT Therapies status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the TIGIT Therapies key companies, revenue, market share, and recent developments.

3. To split the TIGIT Therapies breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions TIGIT Therapies market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify TIGIT Therapies significant trends, drivers, influence factors in global and regions.

6. To analyze TIGIT Therapies competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global TIGIT Therapies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of TIGIT Therapies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of TIGIT Therapies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global TIGIT Therapies industry.

Chapter 3: Detailed analysis of TIGIT Therapies company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of TIGIT Therapies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of TIGIT Therapies in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. TIGIT Therapies Industry Trends Table 2. TIGIT Therapies Industry Drivers Table 3. TIGIT Therapies Industry Opportunities and Challenges Table 4. TIGIT Therapies Industry Restraints Table 5. Global TIGIT Therapies Revenue by Company (US$ Million) & (2021-2026) Table 6. Global TIGIT Therapies Revenue Share by Company (2021-2026) Table 7. Global TIGIT Therapies Company Ranking, (2024-2026) & (US$ Million) Table 8. Global TIGIT Therapies Key Company Manufacturing Base & Headquarters Table 9. Global TIGIT Therapies Company, Product Type & Application Table 10. Global TIGIT Therapies Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global TIGIT Therapies by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Monotherapy Table 15. Significant Companies of Combination Therapy Table 16. Global TIGIT Therapies Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global TIGIT Therapies Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global TIGIT Therapies Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global TIGIT Therapies Sales Value Share by Type (2021-2026) Table 20. Global TIGIT Therapies Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Cell Carcinoma Table 22. Significant Companies of Solid Tumor Table 23. Global TIGIT Therapies Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global TIGIT Therapies Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global TIGIT Therapies Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global TIGIT Therapies Sales Value Share by Application (2021-2026) Table 27. Global TIGIT Therapies Sales Value Share by Application (2027-2032) Table 28. Global TIGIT Therapies Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global TIGIT Therapies Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global TIGIT Therapies Sales Value Share by Region (2021-2026) Table 31. Global TIGIT Therapies Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global TIGIT Therapies Sales Value Share by Region (2027-2032) Table 33. Global TIGIT Therapies Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global TIGIT Therapies Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global TIGIT Therapies Sales Value Market Share by Country (2021-2026) Table 36. Global TIGIT Therapies Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global TIGIT Therapies Sales Value Market Share by Country (2027-2032) Table 38. Arcus Company Information Table 39. Arcus Business Overview Table 40. Arcus TIGIT Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Arcus TIGIT Therapies Product Portfolio Table 42. Arcus Recent Development Table 43. Astellas Company Information Table 44. Astellas Business Overview Table 45. Astellas TIGIT Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Astellas TIGIT Therapies Product Portfolio Table 47. Astellas Recent Development Table 48. BMS Company Information Table 49. BMS Business Overview Table 50. BMS TIGIT Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. BMS TIGIT Therapies Product Portfolio Table 52. BMS Recent Development Table 53. Compugen Company Information Table 54. Compugen Business Overview Table 55. Compugen TIGIT Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Compugen TIGIT Therapies Product Portfolio Table 57. Compugen Recent Development Table 58. Mereo BioPharma Company Information Table 59. Mereo BioPharma Business Overview Table 60. Mereo BioPharma TIGIT Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Mereo BioPharma TIGIT Therapies Product Portfolio Table 62. Mereo BioPharma Recent Development Table 63. Seattle Genetics Company Information Table 64. Seattle Genetics Business Overview Table 65. Seattle Genetics TIGIT Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Seattle Genetics TIGIT Therapies Product Portfolio Table 67. Seattle Genetics Recent Development Table 68. AstraZeneca Company Information Table 69. AstraZeneca Business Overview Table 70. AstraZeneca TIGIT Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. AstraZeneca TIGIT Therapies Product Portfolio Table 72. AstraZeneca Recent Development Table 73. BeiGene Company Information Table 74. BeiGene Business Overview Table 75. BeiGene TIGIT Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. BeiGene TIGIT Therapies Product Portfolio Table 77. BeiGene Recent Development Table 78. Hengrui Medicine Company Information Table 79. Hengrui Medicine Business Overview Table 80. Hengrui Medicine TIGIT Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Hengrui Medicine TIGIT Therapies Product Portfolio Table 82. Hengrui Medicine Recent Development Table 83. Junshi Biosciences Company Information Table 84. Junshi Biosciences Business Overview Table 85. Junshi Biosciences TIGIT Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Junshi Biosciences TIGIT Therapies Product Portfolio Table 87. Junshi Biosciences Recent Development Table 88. Roche Company Information Table 89. Roche Business Overview Table 90. Roche TIGIT Therapies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Roche TIGIT Therapies Product Portfolio Table 92. Roche Recent Development Table 93. Merck Company Information Table 94. Merck Business Overview Table 95. Merck TIGIT Therapies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Merck TIGIT Therapies Product Portfolio Table 97. Merck Recent Development Table 98. Innovent Biologics Company Information Table 99. Innovent Biologics Business Overview Table 100. Innovent Biologics TIGIT Therapies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Innovent Biologics TIGIT Therapies Product Portfolio Table 102. Innovent Biologics Recent Development Table 103. Research Programs/Design for This Report Table 104. Authors List of This Report Table 105. Secondary Sources Table 106. Primary Sources List of Figures Figure 1. TIGIT Therapies Product Image Figure 2. Global TIGIT Therapies Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global TIGIT Therapies Market Size (2021-2032) & (US$ Million) Figure 4. Global TIGIT Therapies Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Monotherapy Image Figure 8. Combination Therapy Image Figure 9. Global TIGIT Therapies Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global TIGIT Therapies Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global TIGIT Therapies Sales Value Share by Type (2021-2032) Figure 12. Cell Carcinoma Image Figure 13. Solid Tumor Image Figure 14. Global TIGIT Therapies Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global TIGIT Therapies Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global TIGIT Therapies Sales Value Share by Application (2021-2032) Figure 17. Global TIGIT Therapies Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global TIGIT Therapies Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America TIGIT Therapies Sales Value (2021-2032) & (US$ Million) Figure 20. North America TIGIT Therapies Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe TIGIT Therapies Sales Value (2021-2032) & (US$ Million) Figure 22. Europe TIGIT Therapies Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific TIGIT Therapies Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific TIGIT Therapies Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America TIGIT Therapies Sales Value (2021-2032) & (US$ Million) Figure 26. South America TIGIT Therapies Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa TIGIT Therapies Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa TIGIT Therapies Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA TIGIT Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA TIGIT Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA TIGIT Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada TIGIT Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada TIGIT Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada TIGIT Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico TIGIT Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico TIGIT Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico TIGIT Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany TIGIT Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany TIGIT Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany TIGIT Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France TIGIT Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France TIGIT Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France TIGIT Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. TIGIT Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. TIGIT Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. TIGIT Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy TIGIT Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy TIGIT Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy TIGIT Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain TIGIT Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain TIGIT Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain TIGIT Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia TIGIT Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia TIGIT Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia TIGIT Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands TIGIT Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands TIGIT Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands TIGIT Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries TIGIT Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries TIGIT Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries TIGIT Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China TIGIT Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China TIGIT Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China TIGIT Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan TIGIT Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan TIGIT Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan TIGIT Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea TIGIT Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea TIGIT Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea TIGIT Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India TIGIT Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India TIGIT Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India TIGIT Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia TIGIT Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia TIGIT Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia TIGIT Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia TIGIT Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia TIGIT Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia TIGIT Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil TIGIT Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil TIGIT Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil TIGIT Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina TIGIT Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina TIGIT Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina TIGIT Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile TIGIT Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile TIGIT Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile TIGIT Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia TIGIT Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia TIGIT Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia TIGIT Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru TIGIT Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru TIGIT Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru TIGIT Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia TIGIT Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia TIGIT Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia TIGIT Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel TIGIT Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel TIGIT Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel TIGIT Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE TIGIT Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE TIGIT Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE TIGIT Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey TIGIT Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey TIGIT Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey TIGIT Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran TIGIT Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran TIGIT Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran TIGIT Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt TIGIT Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt TIGIT Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt TIGIT Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Monotherapy
  • Combination Therapy
Applications
  • Cell Carcinoma
  • Solid Tumor
Companies covered
  • Arcus
  • Astellas
  • BMS
  • Compugen
  • Mereo BioPharma
  • Seattle Genetics
  • AstraZeneca
  • BeiGene
  • Hengrui Medicine
  • Junshi Biosciences
  • Roche
  • Merck
  • Innovent Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global TIGIT Therapies Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global TIGIT Therapies Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 TIGIT Therapies Market Dynamics
  1. 2.1 TIGIT Therapies Industry Trends
  2. 2.2 TIGIT Therapies Industry Drivers
  3. 2.3 TIGIT Therapies Industry Opportunities and Challenges
  4. 2.4 TIGIT Therapies Industry Restraints
3 TIGIT Therapies Market by Company
  1. 3.1 Global TIGIT Therapies Company Revenue Ranking in 2025
  2. 3.2 Global TIGIT Therapies Revenue by Company (2021-2026)
  3. 3.3 Global TIGIT Therapies Company Ranking (2024-2026)
  4. 3.4 Global TIGIT Therapies Company Manufacturing Base and Headquarters
  5. 3.5 Global TIGIT Therapies Company Product Type and Application
  6. 3.6 Global TIGIT Therapies Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global TIGIT Therapies Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 TIGIT Therapies Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 TIGIT Therapies Market by Type
  1. 4.1 TIGIT Therapies Type Introduction
  2. 4.1.1 Monotherapy
  3. 4.1.2 Combination Therapy
  4. 4.2 Global TIGIT Therapies Sales Value by Type
  5. 4.2.1 Global TIGIT Therapies Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global TIGIT Therapies Sales Value by Type (2021-2032)
  7. 4.2.3 Global TIGIT Therapies Sales Value Share by Type (2021-2032)
5 TIGIT Therapies Market by Application
  1. 5.1 TIGIT Therapies Application Introduction
  2. 5.1.1 Cell Carcinoma
  3. 5.1.2 Solid Tumor
  4. 5.2 Global TIGIT Therapies Sales Value by Application
  5. 5.2.1 Global TIGIT Therapies Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global TIGIT Therapies Sales Value by Application (2021-2032)
  7. 5.2.3 Global TIGIT Therapies Sales Value Share by Application (2021-2032)
6 TIGIT Therapies Regional Value Analysis
  1. 6.1 Global TIGIT Therapies Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global TIGIT Therapies Sales Value by Region (2021-2032)
  3. 6.2.1 Global TIGIT Therapies Sales Value by Region: 2021-2026
  4. 6.2.2 Global TIGIT Therapies Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America TIGIT Therapies Sales Value (2021-2032)
  7. 6.3.2 North America TIGIT Therapies Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe TIGIT Therapies Sales Value (2021-2032)
  10. 6.4.2 Europe TIGIT Therapies Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific TIGIT Therapies Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific TIGIT Therapies Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America TIGIT Therapies Sales Value (2021-2032)
  16. 6.6.2 South America TIGIT Therapies Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa TIGIT Therapies Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa TIGIT Therapies Sales Value Share by Country, 2025 VS 2032
7 TIGIT Therapies Country-level Value Analysis
  1. 7.1 Global TIGIT Therapies Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global TIGIT Therapies Sales Value by Country (2021-2032)
  3. 7.2.1 Global TIGIT Therapies Sales Value by Country (2021-2026)
  4. 7.2.2 Global TIGIT Therapies Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA TIGIT Therapies Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA TIGIT Therapies Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA TIGIT Therapies Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada TIGIT Therapies Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada TIGIT Therapies Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada TIGIT Therapies Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico TIGIT Therapies Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico TIGIT Therapies Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico TIGIT Therapies Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany TIGIT Therapies Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany TIGIT Therapies Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany TIGIT Therapies Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France TIGIT Therapies Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France TIGIT Therapies Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France TIGIT Therapies Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. TIGIT Therapies Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. TIGIT Therapies Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. TIGIT Therapies Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy TIGIT Therapies Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy TIGIT Therapies Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy TIGIT Therapies Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain TIGIT Therapies Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain TIGIT Therapies Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain TIGIT Therapies Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia TIGIT Therapies Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia TIGIT Therapies Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia TIGIT Therapies Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands TIGIT Therapies Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands TIGIT Therapies Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands TIGIT Therapies Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries TIGIT Therapies Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries TIGIT Therapies Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries TIGIT Therapies Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China TIGIT Therapies Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China TIGIT Therapies Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China TIGIT Therapies Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan TIGIT Therapies Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan TIGIT Therapies Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan TIGIT Therapies Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea TIGIT Therapies Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea TIGIT Therapies Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea TIGIT Therapies Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India TIGIT Therapies Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India TIGIT Therapies Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India TIGIT Therapies Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia TIGIT Therapies Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia TIGIT Therapies Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia TIGIT Therapies Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia TIGIT Therapies Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia TIGIT Therapies Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia TIGIT Therapies Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil TIGIT Therapies Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil TIGIT Therapies Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil TIGIT Therapies Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina TIGIT Therapies Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina TIGIT Therapies Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina TIGIT Therapies Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile TIGIT Therapies Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile TIGIT Therapies Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile TIGIT Therapies Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia TIGIT Therapies Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia TIGIT Therapies Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia TIGIT Therapies Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru TIGIT Therapies Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru TIGIT Therapies Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru TIGIT Therapies Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia TIGIT Therapies Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia TIGIT Therapies Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia TIGIT Therapies Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel TIGIT Therapies Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel TIGIT Therapies Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel TIGIT Therapies Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE TIGIT Therapies Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE TIGIT Therapies Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE TIGIT Therapies Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey TIGIT Therapies Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey TIGIT Therapies Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey TIGIT Therapies Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran TIGIT Therapies Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran TIGIT Therapies Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran TIGIT Therapies Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt TIGIT Therapies Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt TIGIT Therapies Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt TIGIT Therapies Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Arcus
  2. 8.1.1 Arcus Company Information
  3. 8.1.2 Arcus Business Overview
  4. 8.1.3 Arcus TIGIT Therapies Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Arcus TIGIT Therapies Product Portfolio
  6. 8.1.5 Arcus Recent Developments
  7. 8.2 Astellas
  8. 8.2.1 Astellas Company Information
  9. 8.2.2 Astellas Business Overview
  10. 8.2.3 Astellas TIGIT Therapies Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Astellas TIGIT Therapies Product Portfolio
  12. 8.2.5 Astellas Recent Developments
  13. 8.3 BMS
  14. 8.3.1 BMS Company Information
  15. 8.3.2 BMS Business Overview
  16. 8.3.3 BMS TIGIT Therapies Revenue and Gross Margin (2021-2026)
  17. 8.3.4 BMS TIGIT Therapies Product Portfolio
  18. 8.3.5 BMS Recent Developments
  19. 8.4 Compugen
  20. 8.4.1 Compugen Company Information
  21. 8.4.2 Compugen Business Overview
  22. 8.4.3 Compugen TIGIT Therapies Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Compugen TIGIT Therapies Product Portfolio
  24. 8.4.5 Compugen Recent Developments
  25. 8.5 Mereo BioPharma
  26. 8.5.1 Mereo BioPharma Company Information
  27. 8.5.2 Mereo BioPharma Business Overview
  28. 8.5.3 Mereo BioPharma TIGIT Therapies Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Mereo BioPharma TIGIT Therapies Product Portfolio
  30. 8.5.5 Mereo BioPharma Recent Developments
  31. 8.6 Seattle Genetics
  32. 8.6.1 Seattle Genetics Company Information
  33. 8.6.2 Seattle Genetics Business Overview
  34. 8.6.3 Seattle Genetics TIGIT Therapies Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Seattle Genetics TIGIT Therapies Product Portfolio
  36. 8.6.5 Seattle Genetics Recent Developments
  37. 8.7 AstraZeneca
  38. 8.7.1 AstraZeneca Company Information
  39. 8.7.2 AstraZeneca Business Overview
  40. 8.7.3 AstraZeneca TIGIT Therapies Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AstraZeneca TIGIT Therapies Product Portfolio
  42. 8.7.5 AstraZeneca Recent Developments
  43. 8.8 BeiGene
  44. 8.8.1 BeiGene Company Information
  45. 8.8.2 BeiGene Business Overview
  46. 8.8.3 BeiGene TIGIT Therapies Revenue and Gross Margin (2021-2026)
  47. 8.8.4 BeiGene TIGIT Therapies Product Portfolio
  48. 8.8.5 BeiGene Recent Developments
  49. 8.9 Hengrui Medicine
  50. 8.9.1 Hengrui Medicine Company Information
  51. 8.9.2 Hengrui Medicine Business Overview
  52. 8.9.3 Hengrui Medicine TIGIT Therapies Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Hengrui Medicine TIGIT Therapies Product Portfolio
  54. 8.9.5 Hengrui Medicine Recent Developments
  55. 8.10 Junshi Biosciences
  56. 8.10.1 Junshi Biosciences Company Information
  57. 8.10.2 Junshi Biosciences Business Overview
  58. 8.10.3 Junshi Biosciences TIGIT Therapies Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Junshi Biosciences TIGIT Therapies Product Portfolio
  60. 8.10.5 Junshi Biosciences Recent Developments
  61. 8.11 Roche
  62. 8.11.1 Roche Company Information
  63. 8.11.2 Roche Business Overview
  64. 8.11.3 Roche TIGIT Therapies Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Roche TIGIT Therapies Product Portfolio
  66. 8.11.5 Roche Recent Developments
  67. 8.12 Merck
  68. 8.12.1 Merck Company Information
  69. 8.12.2 Merck Business Overview
  70. 8.12.3 Merck TIGIT Therapies Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Merck TIGIT Therapies Product Portfolio
  72. 8.12.5 Merck Recent Developments
  73. 8.13 Innovent Biologics
  74. 8.13.1 Innovent Biologics Company Information
  75. 8.13.2 Innovent Biologics Business Overview
  76. 8.13.3 Innovent Biologics TIGIT Therapies Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Innovent Biologics TIGIT Therapies Product Portfolio
  78. 8.13.5 Innovent Biologics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst